Lineage Cell Therapeutics Inc Free Cash Flow Generation Index

Latest as of March 2022: 1.00x

Lineage Cell Therapeutics Inc free cash flow generation index. Lineage Cell Therapeutics Inc (LCTX) has a Free Cash Flow Generation Index of 1.00x as of March 2022. Free cash flow of $21.86 Million represents 1% of operating cash flow ($21.90 Million).

FCF Generation Index

1.00x

Free Cash Flow / Operating CF

Free Cash Flow

$21.86 Million

USD

Operating Cash Flow

$21.90 Million

USD

Capital Expenditures

$46.00K

USD

Free Cash Flow Generation Index of Lineage Cell Therapeutics Inc (2022–2022)

Free cash flow generation index of Lineage Cell Therapeutics Inc from 2022 to 2022. Historical FCF Generation Index trend for Lineage Cell Therapeutics Inc across 1 annual periods. See Lineage Cell Therapeutics Inc (LCTX) flexibility index to measure the company's free cash flow as a share of total liabilities.

Lineage Cell Therapeutics Inc Free Cash Flow Generation Index by Year (2022–2022)

Lineage Cell Therapeutics Inc free cash flow generation index by year from 2022 to 2022. Year-by-year Free Cash Flow Generation Index for Lineage Cell Therapeutics Inc. For the full cash flow conversion analysis, see Lineage Cell Therapeutics Inc cash flow conversion.

Year	FCG Index	Free Cash Flow (USD)	Operating CF	Capital Expenditures	YoY Change
2022	0.61x	$646.00K	$1.06 Million	$413.00K	—

FCG Index = Free Cash Flow / Operating Cash Flow. FCF = Operating CF + Capital Expenditures (capex stored negative).